Ann: SubB2M/CA15.3 Clinical Validation Data Investor Presentation, page-30

I just need to point out.....the IIQ share register is predominantly retail shareholders.
The main reason for this is that fund managers, on the whole, are unable to buy stocks with mkt caps below a certain level. This may astound some of you....but it doesn't matter how compelling the fundamental story is, or how much upside is presented by a company's IP....Fund manager mandates dictate!!!
Now it's important to glean from that situation that they find themselves in....that as stupid as it sounds, if they like a stock(and it's story, it's IP, the potential) they may not be able to buy it at a $60mln valuation....but they will be able to buy it at a $150mln valuation, or $200mln, or when it enters the ASX300!

This concept is farcical....but it's reality.

So bare this in mind.....as the company grows in value, the ability of funds to buy the stock increases! If IIQ gets to $2 you will see demand for shares increase, just when you expect selling to increase.

At the moment.....it's just small bio funds, and all retail holding the stock.